Guangzhou LBP Medicine Science & Technology Co., Ltd. Stock

Equities

688393

CNE1000043R4

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. 18:00:00 2024-04-29 EDT 5-day change 1st Jan Change
18.8 CNY -1.26% Intraday chart for Guangzhou LBP Medicine Science & Technology Co., Ltd. +13.39% -24.71%

Financials

Sales 2022 507M 70.08M 96.12M Sales 2023 497M 68.69M 94.21M Capitalization 2.34B 323M 443M
Net income 2022 42M 5.8M 7.96M Net income 2023 40M 5.53M 7.58M EV / Sales 2022 3.57 x
Net cash position 2022 242M 33.38M 45.78M Net cash position 2023 91.86M 12.69M 17.4M EV / Sales 2023 4.51 x
P/E ratio 2022
48.9 x
P/E ratio 2023
59.5 x
Employees -
Yield 2022
0.64%
Yield 2023
-
Free-Float 43.15%
More Fundamentals * Assessed data
Dynamic Chart
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
LBP Medicine Scraps Convertible Bonds Issuance Plans MT
LBP Medicine Gets Certificate for HER2 Antibody Reagent MT
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A Shares of LBP Medicine Science & Technology Co., Ltd are subject to a Lock-Up Agreement Ending on 20-AUG-2023. CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Guangzhou Anbiping Medical Laboratory Co., Ltd. announced that it expects to receive CNY 20 million in funding from Guangzhou LBP Medicine Science & Technology Co., Ltd., Guangzhou Anbiping No. 1 Investment Partnership Enterprise (Limited Partnership), Guangzhou Anbiping No. 2 Investment Partnership Enterprise (Limited Partnership) CI
More news
1 day-1.26%
1 week+13.39%
Current month-3.79%
1 month-3.79%
3 months-7.43%
6 months-23.08%
Current year-24.71%
More quotes
1 week
16.64
Extreme 16.64
19.15
1 month
15.30
Extreme 15.3
20.29
Current year
12.83
Extreme 12.83
25.85
1 year
12.83
Extreme 12.83
34.48
3 years
12.83
Extreme 12.83
41.33
5 years
12.83
Extreme 12.83
74.00
10 years
12.83
Extreme 12.83
74.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 05-07-05
Director of Finance/CFO 41 22-05-15
Chief Administrative Officer 44 07-06-30
Members of the board TitleAgeSince
Chief Executive Officer 59 05-07-05
Director/Board Member 43 17-11-19
Director/Board Member 47 05-10-31
More insiders
Date Price Change Volume
24-04-30 18.8 -1.26% 817,216
24-04-29 19.04 +5.78% 1,505,546
24-04-26 18 +4.23% 1,321,234
24-04-25 17.27 +1.59% 890,654
24-04-24 17 +1.61% 795,107

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 688393 Stock